Only Monoferric is FDA-approved as a single, rapid iron infusion, regardless of patient weight1,a
For patients weighing 50 kg or more: Administer 1000 mg of Monoferric by intravenous infusion ≥20 minutes as a single dose.1
For patients weighing less than 50 kg: Administer Monoferric as 20 mg/kg actual body weight by intravenous infusion ≥20 minutes as a single dose.1
| a | Monoferric is administered as a single, 1-g IV infusion for patients weighing ≥50 kg, or 20 mg/kg for patients <50 kg, over ≥20 minutes. Repeat dose if iron deficiency anemia reoccurs. Patients should be monitored for an additional 30 minutes post-infusion. |
FDA=US Food and Drug Administration.
References: 1. Monoferric (ferric derisomaltose) Prescribing Information; Pharmacosmos Therapeutics Inc., Morristown, NJ: 2022. 2. Data on file. Pharmacosmos Therapeutics Inc. 3. Page RD, Narang M, Polson M. Management of iron deficiency anemia in oncology: intravenous iron discordance in cancer patients. Poster presented at: AMCP 2024; April 15-18, 2024; New Orleans, LA. 4. Upadhyay A, Polson M. Intravenous iron treatment considerations in patients with non-dialysis dependent chronic kidney disease. Poster presented at: AMCP 2024; April 15-18, 2024; New Orleans, LA. 5. Fudim M, Burkle J, Polson M. Managing iron deficiency anemia with heart failure: impact of intravenous iron selection. Poster presented at: ACC 2024; April 6-8, 2024; Atlanta, GA.